{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-056678","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2024-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.765262+00:00","generated_at":"2026-06-01T00:59:14.522764+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Silo Pharma amends license milestones with University of Maryland, Baltimore","bullets":["Fourth Amendment replaces Schedule C diligence milestones under the Master License Agreement.","New milestones include completing in vitro peptide binding by March 2025 and preclinical studies by September 2025.","IND filing for a Licensed Product due by February 2028; first commercial sale by February 2034.","All other terms, including royalty rate and payment obligations, remain unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-056678","json":"https://secwatch.observer/filing/0001213900-24-056678.json","markdown":"https://secwatch.observer/filing/0001213900-24-056678.md","text":"https://secwatch.observer/filing/0001213900-24-056678.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390024056678/0001213900-24-056678-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390024056678/ea0208662-8k_silo.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:59:14.522764+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}